Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.

Le AN, Harton J, Desai H, Powers J, Zelley K, Bradbury AR, Nathanson KL, Shah PD, Doucette A, Freedman GM, Gabriel P, Domchek SM, MacFarland SP, Maxwell KN.

Breast Cancer Res Treat. 2020 Apr 3. doi: 10.1007/s10549-020-05612-7. [Epub ahead of print]

PMID:
32246378
2.

Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes.

Landrith T, Li B, Cass AA, Conner BR, LaDuca H, McKenna DB, Maxwell KN, Domchek S, Morman NA, Heinlen C, Wham D, Koptiuch C, Vagher J, Rivera R, Bunnell A, Patel G, Geurts JL, Depas MM, Gaonkar S, Pirzadeh-Miller S, Krukenberg R, Seidel M, Pilarski R, Farmer M, Pyrtel K, Milliron K, Lee J, Hoodfar E, Nathan D, Ganzak AC, Wu S, Vuong H, Xu D, Arulmoli A, Parra M, Hoang L, Molparia B, Fennessy M, Fox S, Charpentier S, Burdette J, Pesaran T, Profato J, Smith B, Haynes G, Dalton E, Crandall JR, Baxter R, Lu HM, Tippin-Davis B, Elliott A, Chao E, Karam R.

NPJ Precis Oncol. 2020 Feb 24;4:4. doi: 10.1038/s41698-020-0109-y. eCollection 2020.

3.

Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing.

Clark DF, Maxwell KN, Powers J, Lieberman DB, Ebrahimzadeh J, Long JM, McKenna D, Shah P, Bradbury A, Morrissette JJD, Nathanson KL, Domchek SM.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00076. Epub 2019 Aug 19.

4.

Research participants' experiences with return of genetic research results and preferences for web-based alternatives.

Gaieski JB, Patrick-Miller L, Egleston BL, Maxwell KN, Walser S, DiGiovanni L, Brower J, Fetzer D, Ganzak A, McKenna D, Long JM, Powers J, Stopfer JE, Nathanson KL, Domchek SM, Bradbury AR.

Mol Genet Genomic Med. 2019 Sep;7(9):e898. doi: 10.1002/mgg3.898. Epub 2019 Aug 3.

5.

Reply.

MacFarland SP, Katona BW, Maxwell KN.

Gastroenterology. 2019 Jul;157(1):264-265. doi: 10.1053/j.gastro.2019.05.047. Epub 2019 May 28. No abstract available.

PMID:
31150609
6.

Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.

Kraya AA, Maxwell KN, Wubbenhorst B, Wenz BM, Pluta J, Rech AJ, Dorfman LM, Lunceford N, Barrett A, Mitra N, Morrissette JJD, Feldman M, Nayak A, Domchek SM, Vonderheide RH, Nathanson KL.

Clin Cancer Res. 2019 Jul 15;25(14):4363-4374. doi: 10.1158/1078-0432.CCR-18-0468. Epub 2019 Mar 26.

PMID:
30914433
7.

Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome.

MacFarland SP, Zelley K, Long JM, McKenna D, Mamula P, Domchek SM, Nathanson KL, Brodeur GM, Rustgi AK, Katona BW, Maxwell KN.

Gastroenterology. 2019 Jan;156(1):273-274. doi: 10.1053/j.gastro.2018.09.036. Epub 2018 Sep 19. No abstract available.

8.

Rac1 Nanoscale Organization on the Plasma Membrane Is Driven by Lipid Binding Specificity Encoded in the Membrane Anchor.

Maxwell KN, Zhou Y, Hancock JF.

Mol Cell Biol. 2018 Aug 28;38(18). pii: e00186-18. doi: 10.1128/MCB.00186-18. Print 2018 Sep 15.

9.

The differential diagnosis of a TP53 genetic testing result.

MacFarland SP, Maxwell KN.

Genet Med. 2018 Aug;20(8):806-808. doi: 10.1038/gim.2017.250. Epub 2018 Jan 11. No abstract available.

PMID:
29323666
10.

Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer.

Bradbury AR, Patrick-Miller L, Egleston BL, Maxwell KN, DiGiovanni L, Brower J, Fetzer D, Bennett Gaieski J, Brandt A, McKenna D, Long J, Powers J, Stopfer JE, Nathanson KL, Domchek SM.

JCO Precis Oncol. 2018;2. doi: 10.1200/po.17.00250. Epub 2018 Apr 16.

11.

Clustering of Rac1: Selective Lipid Sorting Drives Signaling.

Maxwell KN, Zhou Y, Hancock JF.

Trends Biochem Sci. 2018 Feb;43(2):75-77. doi: 10.1016/j.tibs.2017.11.007. Epub 2017 Nov 30.

PMID:
29198968
12.

Erratum: Author Correction: The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk.

Slavin TP, Maxwell KN, Lilyquist J, Vijai J, Neuhausen SL, Hart SN, Ravichandran V, Thomas T, Maria A, Villano D, Schrader KA, Moore R, Hu C, Wubbenhorst B, Wenz BM, D'Andrea K, Robson ME, Peterlongo P, Bonanni B, Ford JM, Garber JE, Domchek SM, Szabo C, Offit K, Nathanson KL, Weitzel JN, Couch FJ.

NPJ Breast Cancer. 2017 Nov 7;3:44. doi: 10.1038/s41523-017-0046-2. eCollection 2017.

13.

Electronic Health Record Phenotypes for Precision Medicine: Perspectives and Caveats From Treatment of Breast Cancer at a Single Institution.

Breitenstein MK, Liu H, Maxwell KN, Pathak J, Zhang R.

Clin Transl Sci. 2018 Jan;11(1):85-92. doi: 10.1111/cts.12514.

14.

ALLELE-SPECIFIC COPY NUMBER ESTIMATION BY WHOLE EXOME SEQUENCING.

Chen H, Jiang Y, Maxwell KN, Nathanson KL, Zhang N.

Ann Appl Stat. 2017 Jun;11(2):1169-1192. doi: 10.1214/17-AOAS1043. Epub 2017 Jul 20.

15.

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.

Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, Barrett A, Kraya AA, Anastopoulos IN, Yu S, Jiang Y, Chen H, Zhang NR, Hackman N, D'Andrea K, Daber R, Morrissette JJD, Mitra N, Feldman M, Domchek SM, Nathanson KL.

Nat Commun. 2017 Aug 22;8(1):319. doi: 10.1038/s41467-017-00388-9.

16.

Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.

Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A.

Breast Cancer Res Treat. 2017 Aug;164(3):639-640. doi: 10.1007/s10549-017-4339-9. No abstract available.

PMID:
28653249
17.

The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk.

Slavin TP, Maxwell KN, Lilyquist J, Vijai J, Neuhausen SL, Hart SN, Ravichandran V, Thomas T, Maria A, Villano D, Schrader KA, Moore R, Hu C, Wubbenhorst B, Wenz BM, D'Andrea K, Robson ME, Peterlongo P, Bonanni B, Ford JM, Garber JE, Domchek SM, Szabo C, Offit K, Nathanson KL, Weitzel JN, Couch FJ.

NPJ Breast Cancer. 2017 Jun 9;3:22. doi: 10.1038/s41523-017-0024-8. eCollection 2017. Erratum in: NPJ Breast Cancer. 2017 Nov 7;3:44.

18.

Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.

Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A.

Breast Cancer Res Treat. 2017 Aug;164(3):627-638. doi: 10.1007/s10549-017-4257-x. Epub 2017 May 12. Erratum in: Breast Cancer Res Treat. 2017 Jun 26;:.

19.

A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer.

Vijai J, Topka S, Villano D, Ravichandran V, Maxwell KN, Maria A, Thomas T, Gaddam P, Lincoln A, Kazzaz S, Wenz B, Carmi S, Schrader KA, Hart SN, Lipkin SM, Neuhausen SL, Walsh MF, Zhang L, Lejbkowicz F, Rennert H, Stadler ZK, Robson M, Weitzel JN, Domchek S, Daly MJ, Couch FJ, Nathanson KL, Norton L, Rennert G, Offit K.

Cancer Discov. 2016 Nov;6(11):1267-1275. Epub 2016 Sep 21.

20.

Population Frequency of Germline BRCA1/2 Mutations.

Maxwell KN, Domchek SM, Nathanson KL, Robson ME.

J Clin Oncol. 2016 Dec;34(34):4183-4185. Epub 2016 Oct 31. No abstract available.

PMID:
27551127
21.

Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.

Jean S, Li J, Katsaros D, Wubbenhorst B, Maxwell KN, Fishbein L, McLane MW, Benedetto C, Canuto EM, Mitra N, Zhang L, Nathanson KL, Tanyi JL.

Oncotarget. 2016 Jul 26;7(30):48577-48585. doi: 10.18632/oncotarget.9373.

22.

Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.

Maxwell KN, Hart SN, Vijai J, Schrader KA, Slavin TP, Thomas T, Wubbenhorst B, Ravichandran V, Moore RM, Hu C, Guidugli L, Wenz B, Domchek SM, Robson ME, Szabo C, Neuhausen SL, Weitzel JN, Offit K, Couch FJ, Nathanson KL.

Am J Hum Genet. 2016 May 5;98(5):801-817. doi: 10.1016/j.ajhg.2016.02.024.

23.

Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes.

Hart SN, Maxwell KN, Thomas T, Ravichandran V, Wubberhorst B, Klein RJ, Schrader K, Szabo C, Weitzel JN, Neuhausen SL, Nathanson K, Offit K, Couch FJ, Vijai J.

Brief Bioinform. 2016 Jul;17(4):672-7. doi: 10.1093/bib/bbv075. Epub 2015 Sep 10.

24.

Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing.

Bradbury AR, Patrick-Miller LJ, Egleston BL, DiGiovanni L, Brower J, Harris D, Stevens EM, Maxwell KN, Kulkarni A, Chavez T, Brandt A, Long JM, Powers J, Stopfer JE, Nathanson KL, Domchek SM.

Genet Med. 2016 Jan;18(1):25-33. doi: 10.1038/gim.2015.19. Epub 2015 Apr 2.

PMID:
25834950
25.

Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.

Maxwell KN, Wubbenhorst B, D'Andrea K, Garman B, Long JM, Powers J, Rathbun K, Stopfer JE, Zhu J, Bradbury AR, Simon MS, DeMichele A, Domchek SM, Nathanson KL.

Genet Med. 2015 Aug;17(8):630-8. doi: 10.1038/gim.2014.176. Epub 2014 Dec 11.

26.

Common breast cancer risk variants in the post-COGS era: a comprehensive review.

Maxwell KN, Nathanson KL.

Breast Cancer Res. 2013 Dec 20;15(6):212. doi: 10.1186/bcr3591. Review.

27.

Bile acids modulate signaling by functional perturbation of plasma membrane domains.

Zhou Y, Maxwell KN, Sezgin E, Lu M, Liang H, Hancock JF, Dial EJ, Lichtenberger LM, Levental I.

J Biol Chem. 2013 Dec 13;288(50):35660-70. doi: 10.1074/jbc.M113.519116. Epub 2013 Oct 28.

28.

A classic presentation of an uncommon leukemia.

Maxwell KN, Porter DL.

Am J Hematol. 2013 May;88(5):431-2. doi: 10.1002/ajh.23325. Epub 2012 Sep 17. No abstract available.

29.

Cancer treatment according to BRCA1 and BRCA2 mutations.

Maxwell KN, Domchek SM.

Nat Rev Clin Oncol. 2012 Sep;9(9):520-8. doi: 10.1038/nrclinonc.2012.123. Epub 2012 Jul 24. Review.

PMID:
22825375
30.

Antibodies to PCSK9: a superior way to lower LDL cholesterol?

Maxwell KN, Breslow JL.

Circ Res. 2012 Jul 20;111(3):274-7. doi: 10.1161/CIRCRESAHA.112.275859.

PMID:
22821907
31.

The incidence of both serious and minor complications in young women undergoing oocyte donation.

Maxwell KN, Cholst IN, Rosenwaks Z.

Fertil Steril. 2008 Dec;90(6):2165-71. doi: 10.1016/j.fertnstert.2007.10.065. Epub 2008 Feb 4.

PMID:
18249368
32.

Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.

Maxwell KN, Breslow JL.

Curr Opin Lipidol. 2005 Apr;16(2):167-72. Review.

PMID:
15767856
34.

Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

Maxwell KN, Fisher EA, Breslow JL.

Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2069-74. Epub 2005 Jan 27.

35.

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Maxwell KN, Breslow JL.

Proc Natl Acad Sci U S A. 2004 May 4;101(18):7100-5. Epub 2004 Apr 26.

36.

Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice.

Maxwell KN, Soccio RE, Duncan EM, Sehayek E, Breslow JL.

J Lipid Res. 2003 Nov;44(11):2109-19. Epub 2003 Aug 1.

38.

ABO blood groups and hypertension.

MAXWELL RD, MAXWELL KN.

Br Med J. 1955 Jul 16;2(4932):179-80. No abstract available.

Supplemental Content

Loading ...
Support Center